{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:33:53Z","timestamp":1770899633764,"version":"3.50.1"},"reference-count":108,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2004,2]]},"DOI":"10.1080\/1042819031000139666","type":"journal-article","created":{"date-parts":[[2003,11,10]],"date-time":"2003-11-10T12:33:23Z","timestamp":1068467603000},"page":"205-219","source":"Crossref","is-referenced-by-count":43,"title":["Monoclonal Antibodies in the Treatment of Chronic Lymphoid Leukemias"],"prefix":"10.1080","volume":"45","author":[{"given":"TADEUSZ","family":"ROBAK","sequence":"first","affiliation":[{"name":"Department of Hematology, Medical University of \u0141\u00f3d\u017a, Copernicus Memorial Hospital, 93-513 \u0141\u00f3d\u017a, ul. Pabianicka 62, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,8,3]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"495","volume":"256","author":"Kohler G.","year":"1975","unstructured":"Kohler, G. and Milstein, C. (1975) \"Continuous cultures of fused cells secreting antibody of predetined specificity\", Nature, 256, 495\u2013497.","journal-title":"\"Continuous cultures of fused cells secreting antibody of predetined specificity\", Nature"},{"key":"e_1_2_1_3_1","unstructured":"Dyer M.J.S. (2001) \"Historical aspects of the development of antibody therapy of B-cell malignancies.\" In Monoclonal Antibody Therapy of Hematologic Malignancies edited by B.D. Cheson. Pp 1\u201312. Abingdon: Darwin Scientific Publishing Ltd."},{"key":"e_1_2_1_4_1","first-page":"1","volume":"61","author":"Robak T.","year":"1985","unstructured":"Robak, T. and Goldman, J.M. (1985) \"Monoclonal antibodies reacting with myeloid cells\", British Journal of Haematology, 61, 1\u20139.","journal-title":"\"Monoclonal antibodies reacting with myeloid cells\", British Journal of Haematology"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402639"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_2_1_7_1","first-page":"98, 1326\u2014 1331","article-title":"\"Rituximab therapy for patient with B-cell chronic lymphocytic leukaemia\"","author":"Huhn D","year":"2001","unstructured":"Huhn, D, von Schilling, C., Wilhelm, M., Hallek M., Kuse, R., Knauf, W., et al. (2001) \"Rituximab therapy for patient with B-cell chronic lymphocytic leukaemia\", Blood, 98, 1326\u2014 1331.","journal-title":"Blood"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","unstructured":"Keating Mi. O'Brien S. and Albitar M. (2002) \"Emerging information on the use of rituximab in chronic lymphocytic leukaemia\" Seminars in Oncology 29(1 suppl 2) 70\u201374.","DOI":"10.1053\/sonc.2002.30142"},{"key":"e_1_2_1_9_1","first-page":"15, 1567 \u2014 1574","article-title":"\"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leuke-mia\"","author":"Osterborg A.","year":"1997","unstructured":"Osterborg, A., Dyer, M.J., Bunjes, D., Pangalis, G.A., Bastion, Y., Catovsky, D., et al. (1997) \"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leuke-mia\", Journal of Clinical Oncology, 15, 1567 \u2014 1574.","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_1_10_1","first-page":"3891 \u2014 3897","volume":"20","author":"Rai KR.","year":"2002","unstructured":"Rai, KR., Freter, C.E., Mercier, R.J., Cooper, M.R., Mitchell, B.S., Stadtmauer, E.A., et al. (2002) \"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine\", Journal of Clinical Oncology, 20, 3891 \u2014 3897.","journal-title":"\"Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine\", Journal of Clinical Oncology"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0159"},{"key":"e_1_2_1_12_1","first-page":"3554 \u2014 3561","article-title":"\"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine","volume":"99","author":"Keating M.J.","year":"2002","unstructured":"Keating, M.J., Flinn, I., JaM, V., Binet, J.L., Hillmen, P., Byrd, J., et al. (2002) \"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: result of a large international study\", Blood, 99, 3554 \u2014 3561.","journal-title":"result of a large international study\", Blood"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958010-00009"},{"issue":"2","key":"e_1_2_1_14_1","first-page":"s4","article-title":"\"Mechanism of action of rituximab\"","volume":"12","author":"Maloney G","year":"2001","unstructured":"Maloney, G. (2001) \"Mechanism of action of rituximab\", Anti-Cancer Drugs, 12\\(suppl 2), sl\u2014s4.","journal-title":"Anti-Cancer Drugs"},{"key":"e_1_2_1_15_1","first-page":"3, 137\u2014 143","article-title":"\"The CD52 antigen and development of the CAMPATH antibodies\"","author":"Hale G","year":"2001","unstructured":"Hale, G. (2001) \"The CD52 antigen and development of the CAMPATH antibodies\", Cytotherapy, 3, 137\u2014 143.","journal-title":"Cytotherapy"},{"key":"e_1_2_1_16_1","first-page":"12, 574 \u2014 581","article-title":"\"Campath-1H monoclonal antibody therapy\"","author":"Flynn J.M.","year":"2000","unstructured":"Flynn, J.M. and Byrd, J.C. (2000) \"Campath-1H monoclonal antibody therapy\", Current Opinion in Oncology, 12, 574 \u2014 581.","journal-title":"Current Opinion in Oncology"},{"key":"e_1_2_1_17_1","first-page":"693","article-title":"\"Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac (Fv)-P38 (LMB-2)\"","author":"Robbins D.H.","year":"2000","unstructured":"Robbins, D.H., Margulies, I., Stetler-Stevenson, M. and Kreitman, R.J. (2000) \"Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac (Fv)-P38 (LMB-2)\", Clinical Cancer Research, 6, 693\u2013700.","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_1_18_1","first-page":"345, 241 \u2014 247","article-title":"\"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy resistant hairy cell leukemia\"","author":"Kreitman R.J.","year":"2001","unstructured":"Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., Fitzgerald, D.J., et al. (2001) \"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy resistant hairy cell leukemia\", New England Journal of Medicine, 345, 241 \u2014 247.","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_1_19_1","first-page":"435","article-title":"\"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20\"","author":"Relf M.E.","year":"1994","unstructured":"Relf, M.E., Carner, K., Chambers, K.S., Chinn, P.C., Leonard, J.E., Raab, R., et al. (1994) \"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20\", Blood, 83, 435\u2013445.","journal-title":"Blood"},{"key":"e_1_2_1_20_1","first-page":"3900\u2014 3908","article-title":"\"Biologic response of B lymphoma cells to anti- CD20 monoclonal antibody rituximab in vitro","volume":"95","author":"Golay I.","year":"2000","unstructured":"Golay, I., Zaffaroni, L., Vaccari, T., Lazzari, M., Borleri, G.M., Bernasconi, S., et al. (2000) \"Biologic response of B lymphoma cells to anti- CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement- mediated cell lysis\", Blood, 95, 3900\u2014 3908.","journal-title":"CD55 and CD59 regulate complement- mediated cell lysis\", Blood"},{"key":"e_1_2_1_21_1","first-page":"101, 1045 \u2014 105","article-title":"\"Complement mediated lysis by anti-CD20 m Ab correlates with segregation into lipid rafts\"","author":"Cragg M.S.","year":"2003","unstructured":"Cragg, M.S., Morgan, S.M., Chan, H.T., Morgan, B.P., Filatow, A.V., Johnson, P.W., et al. (2003) \"Complement mediated lysis by anti-CD20 m Ab correlates with segregation into lipid rafts\", Blood, 101, 1045 \u2014 1052.","journal-title":"Blood"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0469"},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","first-page":"1644\u2013","DOI":"10.1182\/blood.V91.5.1644","article-title":"1998) \"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies\"","volume":"91","author":"Shan D.","year":"1652","unstructured":"Shan, D., Ledbetter, J.A. and Press, O.W. (1998) \"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies\", Blood, 91, 1644\u20131652.","journal-title":"Blood"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050016"},{"key":"e_1_2_1_25_1","first-page":"12, 177 \u2014 186","article-title":"\"Chimeric anti-CD20 (IDEC-C2B8) mono-clonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs\"","author":"Demidem A.","year":"1997","unstructured":"Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N. and Bonavida, B. (1997) \"Chimeric anti-CD20 (IDEC-C2B8) mono-clonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs\", Cancer Biotherapy and Radiopharmacsuticals, 12, 177 \u2014 186.","journal-title":"Cancer Biotherapy and Radiopharmacsuticals"},{"key":"e_1_2_1_26_1","first-page":"33","article-title":"\"Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro","volume":"87","author":"Chow K.U.","year":"2002","unstructured":"Chow, K.U., Sommerlad, W.D., Boehrer, S., Schneider, B., Seipelt, G., Rummel, M.J., et al. (2002) \"Anti-CD20 antibody (IDEC-C238, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases\", Haematologica, 87, 33\u201343.","journal-title":"role of cytokines, complement, and caspases\", Haematologica"},{"key":"e_1_2_1_27_1","first-page":"2961 \u2014 2966","volume":"20","author":"Alas S.","year":"2000","unstructured":"Alas, S., Bonavida, B. and Emmanouilides, C. (2000) \"Potentia-tion of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxyfilline and rituximab\", Anticancer Research, 20, 2961 \u2014 2966.","journal-title":"\"Potentia-tion of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxyfilline and rituximab\", Anticancer Research"},{"key":"e_1_2_1_28_1","first-page":"800","volume":"114","author":"Di Gaetano N.","year":"2001","unstructured":"Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., et al. (2001) \"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line ressistant to the cytotoxic activity of either drug alone\", British Journal of Haematology, 114, 800\u2013809.","journal-title":"\"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line ressistant to the cytotoxic activity of either drug alone\", British Journal of Haematology"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.34873"},{"key":"e_1_2_1_30_1","first-page":"1765\u2014 1773","article-title":"\"Glucocorti-coids and rituximab in vitro","volume":"100","author":"Rose A.L.","year":"2002","unstructured":"Rose, A.L., Smith, B.E. and Maloney, D.G. (2002) \"Glucocorti-coids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects\", Blood, 100, 1765\u2014 1773.","journal-title":"synergistic direct antiproliferative and apoptotic effects\", Blood"},{"key":"e_1_2_1_31_1","first-page":"2490","article-title":"\"Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells\"","author":"Shan D.","year":"2001","unstructured":"Shan, D., Gopal, A.K. and Press, O.W. (2001) \"Synergistic effects of the fenretidine (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells\", Clinical Cancer Research, 7, 2490\u20132495.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_1_32_1","first-page":"387a","article-title":"\"Pro-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in B-cell chronic lymphocytic leukemia cells measared by fluorohrome labeled inhibitors of caspases (FIICA) assay\"","volume":"100","author":"Smolewski P.","year":"2002","unstructured":"Smolewski, P., Szmigielska, A., Cebula, B., Sobczak, A., Dar-ynkiewicz, Z. and Robak, T. (2002) \"Pro-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in B-cell chronic lymphocytic leukemia cells measared by fluorohrome labeled inhibitors of caspases (FIICA) assay\", Blood, 100\\(suppl 1), 387a.","journal-title":"Blood"},{"key":"e_1_2_1_33_1","first-page":"873","article-title":"\"Removal of T cells from bone marrow for transplantation","volume":"62","author":"Hale G.","year":"1983","unstructured":"Hale, G., Bright, S., Chumbley, G., Hoang, T., Metcalf, D., Munro, A.J., et al. (1983) \"Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement\", Blood, 62, 873\u2013883.","journal-title":"a monoclonal antilymphocyte antibody that fixes human complement\", Blood"},{"key":"e_1_2_1_34_1","first-page":"6088","article-title":"\"Primary structure of CD52\"","author":"Treumann A.","year":"1995","unstructured":"Treumann, A., Lifely, M.R., Schneider, P. and Ferguson, M.A. (1995) \"Primary structure of CD52\", Journal of Biological Chemistry, 270, 6088\u20136099.","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_1_35_1","first-page":"1089 \u2014 1104","article-title":"\"Caspase-mediated cell death in hematological malignancies","volume":"44","author":"Smolewski P.","year":"2003","unstructured":"Smolewski, P., Darynldewicz, Z. and Robak, T. (2003) \"Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment and clinical implications\", Leukemia and Lymphoma, 44, 1089 \u2014 1104.","journal-title":"theoretical considerations, methods of assessment and clinical implications\", Leukemia and Lymphoma"},{"key":"e_1_2_1_36_1","first-page":"18, 99 \u2014 107","article-title":"\"Campath-1H (anti CD52) monoclonal antibody therapy in lymphoproliferative disorders\"","author":"Pangalis G.A.","year":"2001","unstructured":"Pangalis, G.A., Dimopoulou, M.N., Angelopoulou, M.K., Tse-kouras, C., Vassilakopoulos, T.P., Vaiopoulos, G., et al. (2001) \"Campath-1H (anti CD52) monoclonal antibody therapy in lymphoproliferative disorders\", Medical Oncology, 18, 99 \u2014 107.","journal-title":"Medical Oncology"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3257"},{"key":"e_1_2_1_38_1","first-page":"94, 3340\u2014 3348","article-title":"\"Responses in refractory hairy cell leukemia to a recombinant immunotoxin\"","author":"Kreitman R.J.","year":"1999","unstructured":"Kreitman, R.J., Wilson, W.H., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldmann, TA., et al. (1999) \"Responses in refractory hairy cell leukemia to a recombinant immunotoxin\", Blood, 94, 3340\u2014 3348.","journal-title":"Blood"},{"key":"e_1_2_1_39_1","first-page":"693","article-title":"\"Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv) PE 38 (LMB-2)\"","author":"Robbins D.H.","year":"2000","unstructured":"Robbins, D.H., Margulies, I., Stetler-Stevenson, M. and Kreitman, R.J. (2000) \"Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv) PE 38 (LMB-2)\", Clinical Cancer Research, 6, 693\u2013700.","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_1_40_1","first-page":"955","volume":"48","author":"Cordone I.","year":"1995","unstructured":"Cordone, I., Annino, L., Masi, S.P., Pescarmona, E., Rahimi, S., Ferrari, A., et al. (1995) \"Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia\", Journal of Clinical Pathology, 48, 955\u2013960.","journal-title":"\"Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia\", Journal of Clinical Pathology"},{"key":"e_1_2_1_41_1","first-page":"995","article-title":"\"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display\"","author":"Salvatore G.","year":"2002","unstructured":"Salvatore, G., Beers, R., Margulies, I., Kreitman, R.J. and Pastan, I. (2002) \"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display\", Clinical Cancer Research, 8, 995\u20131002.","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_1_42_1","first-page":"5, 481 \u2014 504","article-title":"\"CD22, a B lymphocytic-specific adhesion molecule that regulates antigen receptor signalling\"","author":"Tedder T.F.","year":"1997","unstructured":"Tedder, T.F., Tuscano, J., Sato, S. and Kehrl, J.H. (1997) \"CD22, a B lymphocytic-specific adhesion molecule that regulates antigen receptor signalling\", Annual Review of Immunology, 5, 481 \u2014 504.","journal-title":"Annual Review of Immunology"},{"key":"e_1_2_1_43_1","first-page":"85, 3457 \u2014 3465","article-title":"\"Continuous infusion of the anti-CD22 immunotoxin IgG RFB4-SMPT-dgA in patients with B-cell lymphoma a phase I study\"","author":"Sausville E.A.","year":"1995","unstructured":"Sausville, E.A., Headlee, D., Stetler-Stevenson, M., Jaffe, E.S., Solomon, D., Figg, W.D., et al. (1995) \"Continuous infusion of the anti-CD22 immunotoxin IgG RFB4-SMPT-dgA in patients with B-cell lymphoma a phase I study\", Blood, 85, 3457 \u2014 3465.","journal-title":"Blood"},{"key":"e_1_2_1_44_1","first-page":"439","volume":"2","author":"Brinkmann U","year":"1996","unstructured":"Brinkmann, U. (1996) \"Recombinant immunotoxins protein engineering for cancer therapy\", Molecular Medicine Today, 2, 439\u2013446.","journal-title":"\"Recombinant immunotoxins protein engineering for cancer therapy\", Molecular Medicine Today"},{"key":"e_1_2_1_45_1","first-page":"82, 1277 \u20141287","article-title":"\"Diagnostic application of two color cytometry in 161 cases of hairy cell leukaemia\"","author":"Robbins B.A.","year":"1993","unstructured":"Robbins, B.A., Ellison, DJ., Spinosa, J.C., Carey, CA., Lukes, R.J., Poppema, S., et al. (1993) \"Diagnostic application of two color cytometry in 161 cases of hairy cell leukaemia\", Blood, 82, 1277 \u20141287.","journal-title":"Blood"},{"key":"e_1_2_1_46_1","first-page":"117\u2014 133","volume":"16","author":"Kreitman R.J","year":"2003","unstructured":"Kreitman, R.J. (2003) \"Immunological treatment of hairy- cell leukaemia\", Best Practice and Research Clinical Haematology, 16, 117\u2014 133.","journal-title":"\"Immunological treatment of hairy- cell leukaemia\", Best Practice and Research Clinical Haematology"},{"key":"e_1_2_1_47_1","first-page":"253","article-title":"\"Current status of monoclonal antibody therapy for chronic lymphocytic leukaemia\"","volume":"17","author":"Nabhan C.","year":"2003","unstructured":"Nabhan, C., Dyer, M.J. and Rosen, S.T. (2003) \"Current status of monoclonal antibody therapy for chronic lymphocytic leukaemia\", Oncology (Huntinght) 17, 253\u2013262","journal-title":"Oncology (Huntinght)"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.51.5.364"},{"key":"e_1_2_1_49_1","first-page":"40, 259 \u2014 263","article-title":"\"Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukaemia\"","author":"Almasri N.M.","year":"1992","unstructured":"Almasri, N.M., Duque, RE., Inturrapse, J., Everett, E. and Braylan, R.C. (1992) \"Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukaemia\", Amer-ican Journal of Hematology, 40, 259 \u2014 263.","journal-title":"Amer-ican Journal of Hematology"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1309\/438N-E0FH-A5PR-XCAC"},{"issue":"2","key":"e_1_2_1_51_1","first-page":"75 \u2014 80","article-title":"\"Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukaemia\"","volume":"29","author":"Nabhan C.","year":"2002","unstructured":"Nabhan, C. and Rosen, S.T. (2002) \"Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukaemia\", Seminars in Oncology, 29(1 suppl 2), 75 \u2014 80.","journal-title":"Seminars in Oncology"},{"key":"e_1_2_1_52_1","first-page":"186 \u2014 194","volume":"1","author":"Petryk M.","year":"2000","unstructured":"Petryk, M., and Grossbard, M.L. (2000) \"Rituximab therapy of B-cell neoplasms\", Clinical Lymphoma, 1, 186 \u2014 194.","journal-title":"\"Rituximab therapy of B-cell neoplasms\", Clinical Lymphoma"},{"key":"e_1_2_1_53_1","first-page":"101, 2507 \u2014 251","article-title":"\"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and its prognostic significance\"","author":"Manshouri T.","year":"2003","unstructured":"Manshouri, T., Do, K.A., Wang, X., Giles, F.J., O'Brien, S.M., Safer, H., et al. (2003) \"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and its prognostic significance\", Blood, 101, 2507 \u2014 2513.","journal-title":"Blood"},{"key":"e_1_2_1_54_1","first-page":"300\u2014 306","article-title":"\"Variability in B-cell antigen expression","volume":"2","author":"Rossmann E.D.","year":"2001","unstructured":"Rossmann, E.D., Lundin, J., Lenkei, R., Mellstedt, H. and Osterborg, A. (2001) \"Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies\", The Hematology Journal, 2, 300\u2014 306.","journal-title":"implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies\", The Hematology Journal"},{"key":"e_1_2_1_55_1","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"\"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lym-phoma: half of patients responded to a four-dose treatment program\"","author":"McLaughlin P","year":"1998","unstructured":"McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czucz-man, M.S., Williams, M.E., et al. (1998) \"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lym-phoma: half of patients responded to a four-dose treatment program\", Journal of Clinical Oncology, 16, 2825\u20132833.","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_1_56_1","first-page":"2153\u2014 2164","volume":"19","author":"Byrd J.C.","year":"2001","unstructured":"Byrd, J.C., Murphy, T., Howard, R.S., Lucas, M.S., Goodrich, A., Park, K., et al. (2001) \"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and accep-table toxicity\", Journal of Clinical Oncology, 19, 2153\u2014 2164.","journal-title":"\"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and accep-table toxicity\", Journal of Clinical Oncology"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002779900141"},{"key":"e_1_2_1_58_1","first-page":"69, 129 \u2014 134","article-title":"\"Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukemia: results from a Nordic multicentre study\"","author":"Itala M.","year":"2002","unstructured":"Itala, M., Geisler, CH., Kimby, E., Juvonen, E., Tjonnfjord, G., Karlson, K. and Remes, K (2002) \"Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukemia: results from a Nordic multicentre study\", European Journal of Haematology, 69, 129 \u2014 134.","journal-title":"European Journal of Haematology"},{"key":"e_1_2_1_59_1","first-page":"100, 3115 \u2014 312","article-title":"\"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukaemia\"","author":"Schulz H.","year":"2002","unstructured":"Schulz, H., Klein, S.K., Rehwald, U., Reiser, M., Hinke, A., Knauf, W.U., et al. (2002) \"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukaemia\", Blood, 100, 3115 \u2014 3120.","journal-title":"Blood"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000046958"},{"key":"e_1_2_1_61_1","first-page":"6","article-title":"\"Randomized phase 2 study of fludarabine with concurrent vs. sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia","volume":"101","author":"Byrd J.C.","year":"2003","unstructured":"Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., et al. (2003) \"Randomized phase 2 study of fludarabine with concurrent vs. sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712)\", Blood, 101, 6\u201314.","journal-title":"results from Cancer and Leukemia Group B 9712 (CALG B9712)\", Blood"},{"key":"e_1_2_1_62_1","unstructured":"Byrd J.C. Lucas M. Cheson B.D. and Flinn I.W. (2002) \"Monoclonal antibody therapies for patients with chronic lymphocytic leukaemia\". In: Monoclonal Antibody Therapy of Hematologic Malignancies edited by B.D. Cheson. Pp 91\u2013112. Abingdon Oxfordshire: Darwin Scientific Publishing Ltd."},{"issue":"1","key":"e_1_2_1_63_1","article-title":"\"Clinical relevance of circulating CD20 in patients with chronic lymphocytic leukaemia\"","volume":"96","author":"Manshouri T.","year":"2000","unstructured":"Manshouri, T., Saffer, H., Keating, M. and Albitar, M. (2000) \"Clinical relevance of circulating CD20 in patients with chronic lymphocytic leukaemia\", Blood, 96\\(suppl 1), 369a (abstract).","journal-title":"Blood"},{"key":"e_1_2_1_64_1","first-page":"36\u2014 38","volume":"63","author":"Byrd J.C.","year":"2003","unstructured":"Byrd, J.C., Smith, L., Hackbarth, M.L., Flinn, I.W., Young, D., Proffitt, J.H., et al. (2003) \"Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab\", Cancer Research, 63, 36\u2014 38.","journal-title":"\"Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab\", Cancer Research"},{"key":"e_1_2_1_65_1","first-page":"800","volume":"114","author":"Di Gaetano N.","year":"2001","unstructured":"Di Gaetano, N., Xiao, Y., Erba, E., Bassan, R., Rambaldi, A., Golay, J., et al. (2001) \"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone\", British Journal of Haematology, 114, 800\u2013809.","journal-title":"\"Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone\", British Journal of Haematology"},{"key":"e_1_2_1_66_1","first-page":"2961 \u2014 2966","volume":"20","author":"Alas S.","year":"2000","unstructured":"Alas, S., Bonavida, B. and Emmanouilides, C. (2000) \"Potentia-tion of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifyline and rituximab\", Anticancer Research, 20, 2961 \u2014 2966.","journal-title":"\"Potentia-tion of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifyline and rituximab\", Anticancer Research"},{"key":"e_1_2_1_67_1","first-page":"709","article-title":"\"Inhibition of interleukin 10 by rituximab results in down regulation of bc1-2 and sensitization of B-cell non-Hodgkin's lymphoma to apopto-sis\"","author":"Alas S.","year":"2001","unstructured":"Alas, S., Emmanouilides, C. and Bonavida, B. (2001) \"Inhibition of interleukin 10 by rituximab results in down regulation of bc1-2 and sensitization of B-cell non-Hodgkin's lymphoma to apopto-sis\", Clinical Cancer Research, 7, 709\u2013723.","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_1_68_1","unstructured":"Wierda W. O'Brien S. Albitar M. Lerner S. Phunkett W. Giles F. et al. (2001) \"Combined fludarabine cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia (abstract)\" Blood 98 771a. (Abstract 3210)."},{"key":"e_1_2_1_69_1","unstructured":"Lee E. Zamkoff K. and Gentile T. (2000) \"Rituxan in the treatment of auto-immune hemolytic anemia\" Blood 96(suppl la) 596a (abstract )."},{"key":"e_1_2_1_70_1","first-page":"97, 3995 \u2014 3997","article-title":"\"Anti-CD20 monoclonal antibody for the treatment of severe immune-mediated, pure red cell aplasia and hemolytic anemia\"","author":"Zecca M.","year":"2001","unstructured":"Zecca, M., DiStefano, P., Mobili, B. and Locatelli, F. (2001) \"Anti-CD20 monoclonal antibody for the treatment of severe immune-mediated, pure red cell aplasia and hemolytic anemia\", Blood, 97, 3995 \u2014 3997.","journal-title":"Blood"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.952"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03078.x"},{"key":"e_1_2_1_73_1","first-page":"2092","volume":"16","author":"Gupta N.","year":"2002","unstructured":"Gupta, N., Kavuru, S., Patel, D., Janson, D., Driscoll, N., Ahmed, S., et al. (2002) \"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukaemia\", Leukemia, 16, 2092\u20132095.","journal-title":"\"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukaemia\", Leukemia"},{"key":"e_1_2_1_74_1","first-page":"99, 1096 \u2014 1097","article-title":"\"Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody\"","author":"Iannitto E.","year":"2002","unstructured":"Iannitto, E., Ammatuna, E., Marino, C., Cirrincione, S., Greco, G. and Mariani, G. (2002) \"Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolitic anemia to anti-CD20 monoclonal antibody\", Blood, 99, 1096 \u2014 1097.","journal-title":"Blood"},{"key":"e_1_2_1_75_1","first-page":"1092","volume":"99","author":"Ghazal H","year":"2002","unstructured":"Ghazal, H. (2002) \"Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukaemia\", Blood, 99, 1092\u20131094.","journal-title":"\"Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukaemia\", Blood"},{"key":"e_1_2_1_76_1","first-page":"299 \u2014 301","volume":"3","author":"Marotta G.","year":"2002","unstructured":"Marotta, G., Lenoci, M., Fabbri, A., Tozzi, M. and Lauria, F. (2002) \"Efficacy of rituximab in the treatment of refractory chronic lymphocytic leukemia patient with bone marrow aplasia\", The Hematology Journal, 3, 299 \u2014 301.","journal-title":"\"Efficacy of rituximab in the treatment of refractory chronic lymphocytic leukemia patient with bone marrow aplasia\", The Hematology Journal"},{"key":"e_1_2_1_77_1","first-page":"2260","volume":"100","author":"Hegde UT.","year":"2002","unstructured":"Hegde, UT., Wilson, W.H., White, T. and Cheson, B.D. (2002) \"Rituximab treatment of refractory fludarabine-associated im-mune thrombocytopenia in chronic lymphocytic leukaemia\", Blood, 100, 2260\u20132262.","journal-title":"\"Rituximab treatment of refractory fludarabine-associated im-mune thrombocytopenia in chronic lymphocytic leukaemia\", Blood"},{"key":"e_1_2_1_78_1","first-page":"170\u2014 173","volume":"80","author":"Seipelt G.","year":"2001","unstructured":"Seipelt, G., Bohme, A., Koschmieder, S. and Hoelzer, D. (2001) \"Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome\", Annals of Hematology, 80, 170\u2014 173.","journal-title":"\"Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome\", Annals of Hematology"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190290021597"},{"key":"e_1_2_1_80_1","first-page":"70","article-title":"\"Campath-1H in B-chronic lymphocytic leukemia","volume":"17","author":"Pangalis G.A.","year":"2000","unstructured":"Pangalis, G.A., Dinopoutou, M.N., Angelopoulou, M.K., Tse-kouras, C.H. and Siakantaris, M.P. (2000) \"Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period\", Medical Oncology, 17, 70\u201373.","journal-title":"report on a patient treated thrice in a 3 year period\", Medical Oncology"},{"key":"e_1_2_1_81_1","first-page":"695","article-title":"\"Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine\"","author":"Montillo M.","year":"2002","unstructured":"Montillo, M., Cafro, AM., Tedeschi, A., Brando, B., Oreste, P., Veronese, S., et al. (2002) \"Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine\", Haematologica, 87, 695\u2013700.","journal-title":"Haematologica"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2245"},{"issue":"2","key":"e_1_2_1_83_1","first-page":"75 \u2014 80","article-title":"\"Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukaemia\"","volume":"29","author":"Nabhan C.","year":"2002","unstructured":"Nabhan, C. and Rozeu, S.T. (2002) \"Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic leukaemia\", Seminars in Oncology, 29\\(suppl 2), 75 \u2014 80.","journal-title":"Seminars in Oncology"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.450989.x"},{"key":"e_1_2_1_85_1","first-page":"97, 669 \u2014 672","article-title":"\"In vivo \"purging\" of residual disease in CLL with Campath-1H\"","author":"Dyer M.J.","year":"1997","unstructured":"Dyer, M.J., Kelsey, S.M., Mackay, H.J., Emmett, E., Thornton, P., Hale, G., et al. (1997) \"In vivo \"purging\" of residual disease in CLL with Campath-1H\", British Journal of Haematology, 97, 669 \u2014 672.","journal-title":"British Journal of Haematology"},{"key":"e_1_2_1_86_1","unstructured":"Nabhan C. Tallman M.S. Riley M.B. Fitzpatrick J. Gordon L.I. Gartenhaus R. et al. (2001) \"Phase I study of combining rituximab and Campath-1H in patients with relapsed or refractory chronic lymphocytic leukaemia\" Blood 98(suppl la) 365a (abstract 1536)."},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1952"},{"key":"e_1_2_1_88_1","first-page":"96, 617 \u2014 619","article-title":"\"Subcutaneous CAMPATH-1H in fludar-abine-resistant\/relapsed chronic lymphocytic and B-prolymphocy-tic leukaemia\"","author":"Bowen A.L.","year":"1997","unstructured":"Bowen, A.L., Zomas, A., Emmett, E., Matutes, E., Dyer, M.J. and Catovsky, D. (1997) \"Subcutaneous CAMPATH-1H in fludar-abine-resistant\/relapsed chronic lymphocytic and B-prolymphocy-tic leukaemia\", British Journal of Haematology, 96, 617 \u2014 619.","journal-title":"British Journal of Haematology"},{"key":"e_1_2_1_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703733"},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1080\/146532401753173981"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1062924.x"},{"key":"e_1_2_1_92_1","first-page":"210","volume":"3","author":"Lush R.J.","year":"2001","unstructured":"Lush, R.J., Haynes, A.P., Byrne, J.L., Cull, G.M., Carter, G.I., Pagliuca, A., et al. (2001) \"Allogenic stem-cell transplantation for lymphoproliferative disorders using BE AM \u2014 CAMPATH (\u00b1 fludarabine) conditioning combined with post-transplant donor lymphocyte infusion\", Cytotherapy, 3, 210\u2013208.","journal-title":"\"Allogenic stem-cell transplantation for lymphoproliferative disorders using BE AM \u2014 CAMPATH (\u00b1 fludarabine) conditioning combined with post-transplant donor lymphocyte infusion\", Cytotherapy"},{"issue":"1","key":"e_1_2_1_93_1","first-page":"2683","article-title":"\"Compath-1H therapy in 29 patients with refractory CLL: \"true\" complete remission is an attainable goal\"","volume":"94","author":"Kennedy B.","year":"1999","unstructured":"Kennedy, B., Rawstron, A.C., Evans, P., English, A., Haynes, A.P., Russell, N.H., et al. (1999) \"Compath-1H therapy in 29 patients with refractory CLL: \"true\" complete remission is an attainable goal\", Blood, 94\\(suppl 1), 603a (Abstr 2683).","journal-title":"Blood"},{"key":"e_1_2_1_94_1","first-page":"2419 \u2014 2425","article-title":"\"In vivo CAMPATH-1H prevents graft vs","volume":"96","author":"Kottaridis P.D.","year":"2000","unstructured":"Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S., et al. (2000) \"In vivo CAMPATH-1H prevents graft vs. host disease following nonmyeloablative stem cell transplantation\", Blood, 96, 2419 \u2014 2425.","journal-title":"host disease following nonmyeloablative stem cell transplantation\", Blood"},{"key":"e_1_2_1_95_1","unstructured":"Matutes E. Brito-Babapulle V. Dearden C. Yullie M.R. and Catovsky D. (2001) \"Prolymphocytic leukemia of B- and T-cell types. Biology and therapy\". In Chronic Lymphoid Leukemias. Edited by B.D. Cheson. Pp 525\u2013541. New York Basel: Marcell Dekkeker Inc."},{"key":"e_1_2_1_96_1","first-page":"15, 2667 \u2014 2672","article-title":"\"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody\"","author":"Pawson R.","year":"1997","unstructured":"Pawson, R., Dyer, M.J.S., Barge, R., Matutes, E., Thornton, P.D., Emmett, E., et al. (1997) \"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody\", Journal of Clinical Oncology, 15, 2667 \u2014 2672.","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_1_97_1","first-page":"185","article-title":"\"Levels of expression of CD52 in normal and leukemic B and T cells","volume":"22","author":"Ginaldi L.","year":"1998","unstructured":"Ginaldi, L., De Martinis, M., Matutes, E., Farahat, N., Morilla, R., Dyer, M.J.S., et al. (1998) \"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H\", Leukemia Research, 22, 185\u2013191.","journal-title":"correlation with in vivo therapeutic responses to Campath-1H\", Leukemia Research"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1721"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.1.205"},{"key":"e_1_2_1_100_1","first-page":"43, 149 \u2014 151","article-title":"\"Level of CD20 expression and efficacy of rituximab treatment of patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukaemia\"","author":"Perz J.","year":"2002","unstructured":"Perz, J., Topaly, J., Fruehauf, S., Hensel, M. and Ho A.D. (2002) \"Level of CD20 expression and efficacy of rituximab treatment of patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukaemia\", Leukemia and Lymphoma, 43, 149 \u2014 151.","journal-title":"Leukemia and Lymphoma"},{"key":"e_1_2_1_101_1","first-page":"255","volume":"16","author":"Allsup D.J.","year":"2002","unstructured":"Allsup, D.J. and Cawley, J.C. (2002) \"The diagnosis and treatment of hairy-cell leukaemia\", Blood Reviews, 16, 255\u2013262.","journal-title":"\"The diagnosis and treatment of hairy-cell leukaemia\", Blood Reviews"},{"key":"e_1_2_1_102_1","first-page":"1046","article-title":"\"Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukaemia\"","author":"Lauria F.","year":"2001","unstructured":"Lauria, F., Lenoci, M., Amino, L., Raspadori, D., Marotta, G., Bocchia, M., et al. (2001) \"Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukaemia\", Haematologica, 86, 1046\u20131050.","journal-title":"Haematologica"},{"key":"e_1_2_1_103_1","first-page":"115, 609 \u2014 611","article-title":"\"Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia\"","author":"Hagberg H.","year":"2001","unstructured":"Hagberg, H. and Lundholm, L. (2001) \"Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia\", British Journal of Haematology, 115, 609 \u2014 611.","journal-title":"British Journal of Haematology"},{"key":"e_1_2_1_104_1","first-page":"736","volume":"81","author":"Pollio F.","year":"2002","unstructured":"Pollio, F., Pocali, B., Palmieri, S., Morabito, P., Scalia, G., Del Vecchio, L., et al. (2002) \"Rituximab a useful drug for a repeatedly relapsed hairy cell leukemia patient\", Annals of Hematology, 81, 736\u2013738.","journal-title":"\"Rituximab a useful drug for a repeatedly relapsed hairy cell leukemia patient\", Annals of Hematology"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3875"},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.109004900.x"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02906136"},{"key":"e_1_2_1_108_1","doi-asserted-by":"crossref","unstructured":"Nieva J. Bethel K. and Saven A. (2003) \"Phase II study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia\" Blood (in press).","DOI":"10.1182\/blood-2003-01-0014"},{"key":"e_1_2_1_109_1","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"\"Phase I trial of recombinant immunotoxin anti-Tac (Fv) PE38 (LMB-2) in patients with hematologic malignancies\"","author":"Kreitman R.J.","year":"2000","unstructured":"Kreitman, R.J., Wilson, W.H., White, J.D, Stetler-Stevenson, M., Jaffe, E.S., Giardina, S., et al. (2000) \"Phase I trial of recombinant immunotoxin anti-Tac (Fv) PE38 (LMB-2) in patients with hematologic malignancies\", Journal of Clinical Oncology, 18, 1622\u20131636.","journal-title":"Journal of Clinical Oncology"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1042819031000139666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:49:08Z","timestamp":1770896948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1042819031000139666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1080\/1042819031000139666"],"URL":"https:\/\/doi.org\/10.1080\/1042819031000139666","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}